BridgeMD
SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study
EU CTIS ID: 2025-521560-36-00
What this study is testing
1) To learn about the safety and tolerability of two study treatment regimens in people recently diagnosed with Stage 3 type 1 diabetes. 2) To find out whether the study treatment can help slow the decline of insulin‑producing cells in the pancreas over the course of the study.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must be up to 40 years old and recently diagnosed with Stage 3 type 1 diabetes
- Participants must be up to date with vaccines required by local or national health authorities
- If female, participants must meet conditions that prevent pregnancy during the study (for example, not having started menstruation, being post‑menopausal, having had certain surgeries, or using reliable birth control)
- Participants must have a positive test for at least one antibody linked to type 1 diabetes
- Participants must agree not to take part in other experimental treatments during the study.
You likely can't join if
- Participants cannot have a known allergy or severe reaction to similar medicines or any ingredient in the study treatment
- Participants cannot have taken part in another clinical trial within a set period before joining this study
- Participants cannot have another autoimmune disease that requires immune system affecting treatment (except stable thyroid or celiac disease)
- Participants cannot have serious health problems affecting the heart, liver, kidneys, or immune system, or have uncontrolled diabetes complications
- Participants cannot have certain infections such as HIV, hepatitis B, or hepatitis C
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
- New Zealand
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom; New Zealand; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.